

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date:11.02.2022

The Head- Listing Compliance
BSE Limited
PhirozeJeejeebhoyTowers
Dalal Street
Mumbai-400001

Scrip Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, i.e. **Friday, 11th day of February, 2022**(commenced at **11:30 A.M.** and concluded at **12:30 P.M**), has inter alia approved and passed the following resolutions:

1. The **Unaudited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended December 31, 2021.**(Copy enclosed)**
2. Took note of the **Limited Review Report** as per Annexure V of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for the quarter and ended December 31, 2021.**(Copy enclosed)**
3. Took note of Statement of Investor Complaints/Grievances under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended December 31, 2021.
4. Took note of The Reconciliation of Share Capital Audit Report Regulation 76 of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2021.
5. Took note of Shareholding pattern pursuant to Regulation 31 of the (Listing Obligations and Disclosure Requirements) Regulation 2015 for the quarter ended December 31, 2021.
6. Took note of Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018for the quarter ended December 31, 2021.

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Kindly take the above information on your records.

Thanking you,

ForRaymed Labs Limited

AJAI
GOYAL

Digitally signed
by AJAI GOYAL
Date: 2022.02.11
12:47:27 +05'30'

AjaiGoyal

Whole Time Director

DIN: 02636418

Place: Noida



**LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE
QUARTER AND NINE MONTHS ENDED ON 31TH DECEMBER, 2021**

To

The Board of Directors

Raymed Labs Limited

103 Emperor 1, Supertech Emerald Court,
Sector 93A, Noida - 201304

1. We have reviewed the accompanying statement of unaudited financial results ("The Statement") of Raymed Labs Limited ("The Company") for the period ended on 31th December, 2021, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Deepak





A. KAY. MEHRA & CO.

C H A R T E R E D A C C O U N T A N T S

2470 (BASEMENT), HUDSON LINE,
G.T.B. NAGAR, DELHI-110009
NEAR GTB NAGAR METRO STATION,
Ph. No.: 011- 42461274, 9891295255
E- Mail: akmca1969@gmail.com
Website: www.akmca.in

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. Kay. Mehara & Co.

Chartered Accountants

(F.R.N. 050004C)

Deepak Suneja


Date: February 11, 2022

Place: Noida

UDIN: 22501957ABIEZR3064

Deepak Suneja

(Partner)

(Membership NO- 501957)

Statement of Standalone Unaudited Financial Results for the Quarter ended December 31, 2021

Particulars	Amt. (In Lacs)					
	Quarter Ended			Nine Months Ended		Year Ended
	31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	0.00	0.00	0.00	0.00	0.00	0.00
II. Other Income	0.00	0.00	0.00	0.00	0.66	0.66
III. Total Income (I +II)	0.00	0.00	0.00	0.00	0.66	0.66
IV. Expenses						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.95	0.78	0.65	2.17	1.10	2.00
Finance Costs	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation and amortisation expenses	0.13	0.13	0.14	0.39	0.43	0.57
Other Expenses	0.55	0.36	0.57	1.20	1.22	4.97
Total Expenses (IV)	1.63	1.27	1.36	3.76	2.75	7.54
V. Profit/(Loss) before exceptional items and tax (III- IV)	-1.63	-1.27	-1.36	-3.76	-2.09	-6.88
VI. Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	-1.63	-1.27	-1.36	-3.76	-2.09	-6.88
VIII. Tax Expense						
(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00	0.00
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-1.63	-1.27	-1.36	-3.76	-2.09	-6.88
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-1.63	-1.27	-1.36	-3.76	-2.09	-6.88
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the Period)	-1.63	-1.27	-1.36	-3.76	-2.09	-6.88
XVI. Paid-up Equity Capital (Face Value of Rs. ___ each)	427.35	427.35	427.35	427.35	427.350	427.35
XVII. Other Equity	0.00	0.00	0.00	0.00	0.00	-632.64
XIX. Earnings per equity share (for continuing operation):						
(1) Basic	-0.0382	-0.0297	-0.0032	-0.0880	-0.0049	-0.1611
(2) Diluted	-0.0382	-0.0297	-0.0032	-0.0880	-0.0049	-0.1611
XX. Earnings per equity share (for discontinued operation):						
(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000
XXI. Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	-0.0382	-0.0297	-0.0032	-0.0880	-0.0049	-0.1611
(2) Diluted	-0.0382	-0.0297	-0.0032	-0.0880	-0.0049	-0.1611

Notes:
(1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 11th, February 2022. The Statutory Auditors have carried out their limited review of the above results.
(2) The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
(3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
(4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification
(5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

For Raymed Labs Limited

AJAI GOYAL
Digitally signed by AJAI GOYAL
 DN: cn=Ajai Goyal, o=Raymed Labs Limited, email=ajai.goyal@raymedlabs.com, c=IN

Ajai Goyal
 Wholtime Director
 DIN: 02636418

Date: 11.02.2022
 Place : Noida

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 11.02.2022

The Head- Listing Compliance

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai-400001

Scrip Code: 531207

Subject: Non Applicability of Compliance with Statement of Deviation(s) or Variation(s) as per Regulation 32 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- For the quarter ended December 31, 2021

Dear Sir/Madam,

With reference to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the disclosure of Statement of Deviation(s) or Variation(s) under the said regulation is not applicable to the Company.

Kindly take the same in your records.

Thanking You,

Yours Sincerely,

For Raymed Labs Limited

AJAI GOYAL Digitally signed by AJAI
GOYAL
Date: 2022.02.11 12:44:37
+05'30'

Ajai Goyal

Whole Time Director

DIN: 02636418

Place: Noida